MX2012004074A - Pirimidonas fusionadas de tiazolo y oxazolo. - Google Patents

Pirimidonas fusionadas de tiazolo y oxazolo.

Info

Publication number
MX2012004074A
MX2012004074A MX2012004074A MX2012004074A MX2012004074A MX 2012004074 A MX2012004074 A MX 2012004074A MX 2012004074 A MX2012004074 A MX 2012004074A MX 2012004074 A MX2012004074 A MX 2012004074A MX 2012004074 A MX2012004074 A MX 2012004074A
Authority
MX
Mexico
Prior art keywords
pyrimidinones
oxazolo
compounds
pharmaceutically acceptable
present
Prior art date
Application number
MX2012004074A
Other languages
English (en)
Inventor
Sanjay Srivastava
Laxmikant Chhipa
Ramesh Chandra Gupta
Shailesh Deshpande
Anita Chaudhari
Anookh Mohanan
Chaitanya Dutt
Vijay Chauthaiwale
Murali Badanthadka
Prashant G Jamadarkhana
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of MX2012004074A publication Critical patent/MX2012004074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos novedosos, sus sales farmacéuticamente aceptables, y sus isómeros, esteroisómeros, conformadores, tautómeros, polimorfos, hidratos y solvatos. La presente invención también abarca composiciones farmacéuticamente aceptables de dichos compuestos y procesos para la preparación de compuestos novedosos. La invención, además, se relaciona con el uso de los compuestos antes mencionados para la preparación de medicamentos para su uso como farmacéuticos.
MX2012004074A 2009-10-13 2010-08-31 Pirimidonas fusionadas de tiazolo y oxazolo. MX2012004074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1249KO2009 2009-10-13
PCT/IN2010/000579 WO2011045811A1 (en) 2009-10-13 2010-08-31 Fused thiazolo and oxazolo pyrimidinones

Publications (1)

Publication Number Publication Date
MX2012004074A true MX2012004074A (es) 2012-05-22

Family

ID=43034589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004074A MX2012004074A (es) 2009-10-13 2010-08-31 Pirimidonas fusionadas de tiazolo y oxazolo.

Country Status (27)

Country Link
EP (1) EP2385948B1 (es)
JP (1) JP5681195B2 (es)
KR (1) KR101710430B1 (es)
CN (1) CN102549000B (es)
AR (1) AR080616A1 (es)
AU (1) AU2010307984B2 (es)
BR (1) BR112012006233B8 (es)
CA (1) CA2772995C (es)
CY (1) CY1119710T1 (es)
DK (1) DK2385948T3 (es)
EA (1) EA020228B1 (es)
ES (1) ES2653931T3 (es)
HR (1) HRP20171976T1 (es)
HU (1) HUE038051T2 (es)
IL (1) IL219116A (es)
LT (1) LT2385948T (es)
MX (1) MX2012004074A (es)
MY (1) MY157629A (es)
NO (1) NO2385948T3 (es)
NZ (1) NZ598020A (es)
PL (1) PL2385948T3 (es)
RS (1) RS56630B1 (es)
SI (1) SI2385948T1 (es)
TW (1) TWI500623B (es)
UA (1) UA107473C2 (es)
WO (1) WO2011045811A1 (es)
ZA (1) ZA201203262B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI661828B (zh) 2013-05-14 2019-06-11 印度商托仁特生技有限公司 低劑量藥物組合物及其用途
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CN106905348B (zh) * 2017-02-13 2018-12-04 牡丹江医学院 一种预防和治疗急性肾损伤的药物及其制备方法和用途
CN110511233B (zh) * 2019-08-08 2022-01-25 成都大学 一种噻唑并[2,3-b]噁唑酮类化合物及其制备方法和用途
CN112778333B (zh) * 2021-01-23 2022-07-05 中国科学院新疆理化技术研究所 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072679A (en) * 1976-06-15 1978-02-07 E. R. Squibb & Sons, Inc. 1,4- AND 4,10-DIHYDRO-4-OXO-PYRIMIDO (1,2-A)-benzimidazole-3-carboxylic acids, esters and amides
DK151811C (da) * 1979-11-23 1988-06-06 Pfizer Analogifremgangsmaade til fremstilling af n-(5-tetrazolyl)-1-oxo-1h-thiazolooe3,2-aaa-pyrimidin-2-carboxamider eller farmaceutisk acceptable kationsalte deraf samt 1-oxo-1h-thiazolooe3,2-aaapyrimidin-2-carboxylsyrer til anvendelse som udgangsmaterialer ved fremgangsmaaden
US4423048A (en) 1979-11-23 1983-12-27 Pfizer Inc. Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor
JPH0539293A (ja) 1991-01-23 1993-02-19 Kyowa Hakko Kogyo Co Ltd 免疫調節剤及びチアゾロピリミジン誘導体
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
KR20050110612A (ko) 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2007115315A2 (en) * 2006-04-04 2007-10-11 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
WO2009039321A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039322A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Also Published As

Publication number Publication date
CN102549000A (zh) 2012-07-04
BR112012006233B1 (pt) 2021-05-18
UA107473C2 (uk) 2015-01-12
CA2772995C (en) 2018-03-13
RS56630B1 (sr) 2018-03-30
JP5681195B2 (ja) 2015-03-04
SI2385948T1 (en) 2018-04-30
CN102549000B (zh) 2015-12-02
EA020228B1 (ru) 2014-09-30
CY1119710T1 (el) 2018-06-27
LT2385948T (lt) 2018-01-10
DK2385948T3 (en) 2017-12-04
ZA201203262B (en) 2013-01-30
NO2385948T3 (es) 2018-03-03
HUE038051T2 (hu) 2018-10-29
AU2010307984A1 (en) 2012-03-01
AR080616A1 (es) 2012-04-25
JP2013507435A (ja) 2013-03-04
NZ598020A (en) 2013-11-29
AU2010307984B2 (en) 2013-11-07
HRP20171976T1 (hr) 2018-02-09
KR101710430B1 (ko) 2017-02-27
KR20120093907A (ko) 2012-08-23
BR112012006233A2 (pt) 2020-08-11
WO2011045811A1 (en) 2011-04-21
TWI500623B (zh) 2015-09-21
BR112012006233B8 (pt) 2021-05-25
IL219116A (en) 2016-05-31
EA201270556A1 (ru) 2013-01-30
IL219116A0 (en) 2012-06-28
CA2772995A1 (en) 2011-04-21
ES2653931T3 (es) 2018-02-09
EP2385948A1 (en) 2011-11-16
EP2385948B1 (en) 2017-10-04
MY157629A (en) 2016-07-15
PL2385948T3 (pl) 2018-02-28
TW201113290A (en) 2011-04-16

Similar Documents

Publication Publication Date Title
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
MX2012002997A (es) Derivados de eter de los heteroarilos biciclicos.
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MY157017A (en) Sulfonamide derivatives
PH12015500376A1 (en) Novel bicyclic pyridinones
WO2010092090A3 (en) Novel salts of sitagliptin
PH12016501903B1 (en) Novel fused imidazobenzothiazole compounds
IN2012DN03182A (es)
IN2014MN01756A (es)
WO2012103226A3 (en) Bendamustine formulations
PH12017501830A1 (en) Novel pyridinium compounds
CY1119710T1 (el) Συντηγμενες θειαζολο- και οξαζολο-πυριμιδινονες
MX2012002608A (es) Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2013006768A (es) Moduladores de receptor de glucagon.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2011012859A (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
MX2012007783A (es) Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
EA201290344A1 (ru) БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ЛИГАНДОВ αβНИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА
PH12017500323B1 (en) P38 map kinase inhibiting indanyl urea compounds
GEP20156269B (en) New secondary 8-hydroxyquinoline-7- carboxamide derivatives
MX2010003056A (es) Polimorfos de valomaciclovir.

Legal Events

Date Code Title Description
FG Grant or registration